Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial

IMPORTANCE: The monoclonal antibody combination of casirivimab and imdevimab reduced viral load, hospitalization, or death when administered as a 1200-mg or greater intravenous (IV) dose in a phase 3 COVID-19 outpatient study. Subcutaneous (SC) and/or lower IV doses should increase accessibility and...

Descripción completa

Detalles Bibliográficos
Autores principales: Portal-Celhay, Cynthia, Forleo-Neto, Eduardo, Eagan, Will, Musser, Bret J., Davis, John D., Turner, Kenneth C., Norton, Thomas, Hooper, Andrea T., Hamilton, Jennifer D., Pan, Cynthia, Mahmood, Adnan, Baum, Alina, Kyratsous, Christos A., Kim, Yunji, Parrino, Janie, Kampman, Wendy, Roque-Guerrero, Lilia, Stoici, Roxana, Fatakia, Adil, Soo, Yuhwen, Geba, Gregory P., Kowal, Bari, DiCioccio, A. Thomas, Stahl, Neil, Lipsich, Leah, Braunstein, Ned, Herman, Gary A., Yancopoulos, George D., Weinreich, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379747/
https://www.ncbi.nlm.nih.gov/pubmed/35969402
http://dx.doi.org/10.1001/jamanetworkopen.2022.25411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379747/
https://www.ncbi.nlm.nih.gov/pubmed/35969402
http://dx.doi.org/10.1001/jamanetworkopen.2022.25411

Ejemplares similares